Semper Paratus Acquisition Corporation
LGSTU
NASDAQ Global Market6.10
USD
+0.56
- -
CIK
0001860871
ISIN
KYG8028L1234
Return %
Stock
S&P500
1Y
-45.09
26.53
3Y
-39.48
76.60
5Y
-39.48
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Surendra K. Ajjarapu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 767 Third Avenue New York City NY United States of America 10017
- IPO Date
- Nov 4, 2021
- CIK
- 0001860871
- Website
- semperparatusspac.com
- Similar Companies
- Business
- Semper Paratus Acquisition Corporation (LGSTU) is a former special purpose acquisition company (SPAC) that completed a business combination with Tevogen Bio Inc. in February 2024 and now operates as Tevogen Bio Holdings Inc. (Nasdaq: TVGN). The combined entity focuses on developing off-the-shelf, genetically unmodified precision T cell therapies and immunotherapies targeting infectious diseases, oncology, neurology, and related conditions such as COVID-19, Long COVID, liver cancer prevention in chronic Hepatitis B patients, and multiple sclerosis; key pipeline products include TVGN 489, an investigational therapy for immunocompromised and elderly patients with COVID-19, TVGN 116 for liver cancer prevention, and AI-enhanced platforms like PredicTcell under Tevogen.AI for accelerating drug development target analysis. Headquartered in Warren, New Jersey, the company was founded in 2020, went public via IPO in November 2021 raising approximately $345 million (with 102% cash in trust), and primarily targeted sectors including transportation, supply chain, logistics, technology, healthcare, and renewable energy prior to its merger. In June 2023, Semper Paratus announced a definitive merger agreement with Tevogen Bio at a pro forma enterprise value of $1.2 billion, including a PIPE commitment; shareholder approval occurred in January 2024 with closing on February 14, 2024, after which the company redomesticated from the Cayman Islands to Delaware, changed its name to Tevogen Bio Holdings Inc., and listed common stock and warrants on Nasdaq under TVGN and TVGNW. Post-merger, Tevogen Bio Holdings has expanded its pipeline to include patients aged 65+ for TVGN 489 amid new COVID variants, secured an $8 million grant (part of $10 million total) from the state of New Jersey to advance Tevogen.AI in partnership with Microsoft, reported Q3 2025 GAAP operating losses with improvements via cost efficiencies, and projected rNPV valuations of $9-11 billion for TVGN 489 alongside $6.5 billion in five-year top-line revenue for TVGN 116. The company serves global patient populations in virology, oncology, and neurology, with operations centered in the United States and Canada, and emphasizes sustainable, affordable biotech solutions through AI integration and strategic R&D investments.